Fig. 2

MRD detection by MFC in ovarian tissue from leukemia patients. The observed populations are indicated at the top of the dot plots (CD45^low, see Fig. 1). A B-ALL patient (patient 1) with negative MRD in the ovarian cortical tissue. (1) B-ALL cells at diagnosis express the following immunophenotype: CD19⁺/CD10⁺/CD22⁺/CD20^+low. (2) Ovarian cells from patient 1: in 449 438 events acquired, we identified no event presenting the same phenotype as the B-ALL cells at diagnosis (P1 ∩ P2 ∩ P3 ∩ P4 ∩ P5). (3) Ovarian cells from patient 1 artificially contaminated with B-ALL cells: in 540 035 events acquired (CD45^low events), we identify 118 events presenting the same phenotype as the B-ALL cells (P1 ∩ P2 ∩ P3 ∩ P4 ∩ P5): the artificial MRD level is quantified at 2.2 × 10^–4. B AML patient (patient 14) with positive MRD in the ovarian tissue. (1) Healthy ovarian tissue (control): there is no event presenting an AML immunophenotype (CD33⁺/CD38⁺/CD34^low/CD117^+low). (2) Ovarian cortical cells from patient 14: in 267 702 events acquired, we identified 75 events presenting the same phenotype as the AML cells at diagnosis (P1 ∩ P2 ∩ P3 ∩ P4 ∩ P5). The MRD level is quantified at 2.8 × 10^–4. (2) Ovarian medulla cells from patient 14: in 738 895 events acquired, we identified 1 233 events presenting the same phenotype as the AML cells at diagnosis (P1 ∩ P2 ∩ P3 ∩ P4 ∩ P5). The MRD level is quantified at 1.7 × 10^–3